Viatris (VTRS) has been attracting attention from investors and analysts as the company continues to expand its portfolio, notably launching
Inpefa (Sotagliflozin) to treat
heart failure. This launch comes amidst a revaluation period for the company, which recently experienced an increase in its share price following multi-year lows. Analysts from
Argus Research and
Barclays have upgraded their view on the company, with the former institution upgrading it to a
'Buy' and the latter initiating coverage with an
'Overweight' rating. Despite this, some shareholders are considering selling VTRS shares as they seek better investment opportunities. The company's valuation has also become a point of focus following its maiden international Inpefa launch. Viatris' commitment to transformation is underscored by the appointment of
Lara Ramsburg as
Chief People and Corporate Affairs Officer. A significant factor supporting the company's bullish trajectory is its Q3
earnings beat, resulting in a share price jump. Despite these positive developments, Viatris is facing a class-action lawsuit regarding a FDA inspection.
Viatris VTRS News Analytics from Thu, 27 Feb 2025 08:00:00 GMT to Sat, 24 Jan 2026 06:09:17 GMT -
Rating 7
- Innovation 2
- Information 7
- Rumor -2
